Trials / Terminated
TerminatedNCT01152216
An Extension of the CONCERT Protocol (DIM18)
An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 672 (actual)
- Sponsor
- Medivation, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
An open-label extension study of the CONCERT (DIM18) protocol evaluating the safety of dimebon (latrepirdine) in subjects with With Mild-to-Moderate Alzheimer's Disease on Donepezil.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dimebon | 20 mg orally three times daily |
Timeline
- Start date
- 2010-04-01
- Primary completion
- 2012-05-01
- First posted
- 2010-06-29
- Last updated
- 2016-09-27
Source: ClinicalTrials.gov record NCT01152216. Inclusion in this directory is not an endorsement.